Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 15/20 | 0.39 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.35 |
| ▸ | CDC7 | O00311 | 2/20 | 0.33 |
| ▸ | DBF4 | Q9UBU7 | 2/20 | 0.33 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29964405 | 0.87 | CDC7 (0.37) | MAPKAPK2CDC7MAPK1 | |
| SCHEMBL27160046 | 0.83 | MAPKAPK2 (0.34) | MAPKAPK2DGAT1CDC7DBF4MAP4K1 | |
| SCHEMBL29964994 | 0.78 | MKNK1 (0.37) | MAP4K1 | |
| SCHEMBL29964097 | 0.78 | MAPK1 (0.53) | MAPKAPK2MAPK1 | |
| SCHEMBL29965169 | 0.76 | FYN (0.38) | — | |
| SCHEMBL29964550 | 0.76 | GSK3B (0.45) | MAPKAPK2MAPK1 | |
| SCHEMBL18937005 | 0.75 | NOS1 (0.38) | MAPKAPK2CDC7DBF4MAP4K1MAPK1 | |
| SCHEMBL31079382 | 0.73 | HTT (0.41) | MAPKAPK2CDC7MAPK1 | |
| SCHEMBL27160212 | 0.71 | PARP10 (0.32) | — | |
| SCHEMBL24457369 | 0.71 | PARP10 (0.46) | MAPKAPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240343704-A1 | HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2024-10-17 | — | — | US | disclosed |
| WO-2022226668-A1 | HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2022-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240343704-A1 | HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | CMPK1, WNK1, AAK1 | MAPKAPK2 79/4885DGAT1 3546/4885CDC7 206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.